Skip to content




CAR-TCR Industry Survey Results 2019

Here’s what your peers think about key developments and priorities in this rapidly evolving field.

View Survey Results

CART Industry Survey Snippet

Press Release: Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology

View the Full Press Release

CAR-TCR Conversion with

Peter Emtage, Senior Vice President, Head of Cell Therapy Research, Kite, a Gilead Company

In this conversation, Peter shares his views on the clinical and commercial progression of CAR-T therapies after a whirlwind few years.

View Full Interview

CAR-TCR Conversation with David Sourdive Executive Vice President, Technical Operations & Co-founder


In this conversation, David discusses the disruptive genetic engineering approaches developed to create efficacious, next generation CAR and TCR therapies


CAR-TCR Industry Survey 2018

The infographic provides some great insights into solid tumor approaches, commercial impact and limitations of manufacturing strategies.


Interviews with: Juno Therapeutics, Cellectis, ZIOPHARM, Kite Pharma

On a mission to find out what the future holds for the CAR-TCR space, we sat down with: Hans Bishop, CEO, Juno Therapeutics; André Choulika, CEO, Cellectis; Laurence Cooper, CEO, ZIOPHARM and David Chang, CMO, Kite, Pharma to talk shop.

Speaker Interview

CAR-TCR Industry Survey 2017

The industry results provide some great insights into manufacturing challenges, key design factors for the next generation of CAR-TCR therapies and pricing models for these therapies.


Major Highlights of the CAR-TCR Summit, Boston 2016

Vita Golubovskaya, Robert Berahovich, Shirley Xu, Hizkia Harto and Lijun Wu present their highlights from the CAR-TCR Summit 2016